CONSUN PHARMAC.GR.HD -10 Total Assets
CONSUN PHARMAC.GR.HD -10 total assets. Based on the latest financial reports, CONSUN PHARMAC.GR.HD -10 (C1P) holds total assets worth €6.41 Billion EUR (≈ $7.49 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CONSUN PHARMAC.GR.HD -10 (C1P) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of CONSUN PHARMAC.GR.HD -10 (2021–2025)
Total assets of CONSUN PHARMAC.GR.HD -10 from 2021 to 2025. This chart illustrates how CONSUN PHARMAC.GR.HD -10's total assets have evolved over time, based on quarterly financial data. See CONSUN PHARMAC.GR.HD -10 stock quote for real-time trading data and today's change.
CONSUN PHARMAC.GR.HD -10 - Asset Composition Analysis
CONSUN PHARMAC.GR.HD -10 Total Assets Breakdown (December 2025)
CONSUN PHARMAC.GR.HD -10 total assets breakdown as of December 2025. CONSUN PHARMAC.GR.HD -10's total assets of €6.41 Billion consist of 71.8% current assets and 28.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 19.3% |
| Accounts Receivable | €251.32 Million | 3.9% |
| Inventory | €271.40 Million | 4.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €373.62 Million | 5.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how CONSUN PHARMAC.GR.HD -10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CONSUN PHARMAC.GR.HD -10 (C1P) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CONSUN PHARMAC.GR.HD -10's current assets represent 71.8% of total assets in 2025, an increase from 70.0% in 2021.
- Cash Position: Cash and equivalents constituted 19.3% of total assets in 2025, down from 50.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 10.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 5.8% of total assets.
CONSUN PHARMAC.GR.HD -10 Competitors by Total Assets
Key competitors of CONSUN PHARMAC.GR.HD -10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
CONSUN PHARMAC.GR.HD -10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.22 | 3.32 | 3.06 |
| Quick Ratio | 3.03 | 3.11 | 2.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.17 Billion | €3.18 Billion | €2.86 Billion |
CONSUN PHARMAC.GR.HD -10 - Advanced Valuation Insights
This section examines the relationship between CONSUN PHARMAC.GR.HD -10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.37 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 9.5% |
| Total Assets | €6.41 Billion |
| Market Capitalization | $1.35 Billion USD |
Valuation Analysis
Below Book Valuation: The market values CONSUN PHARMAC.GR.HD -10's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CONSUN PHARMAC.GR.HD -10's assets grew by 9.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CONSUN PHARMAC.GR.HD -10 (2021–2025)
The table below shows the annual total assets of CONSUN PHARMAC.GR.HD -10 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €6.41 Billion ≈ $7.49 Billion |
+9.52% |
| 2024-12-31 | €5.85 Billion ≈ $6.84 Billion |
+6.27% |
| 2023-12-31 | €5.51 Billion ≈ $6.44 Billion |
+12.58% |
| 2022-12-31 | €4.89 Billion ≈ $5.72 Billion |
+12.14% |
| 2021-12-31 | €4.36 Billion ≈ $5.10 Billion |
-- |
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more